There Will Be Healthy Competition Between India And China - Two Emerging Biotech Superpowers - Says Reinhard Gluck, Research Head At Zydus Cadila And Chairman, Swiss Biotech Association
This article was originally published in PharmAsia News
Executive Summary
Reinhard Gluck, chairman of the Swiss Biotech Association, had lucrative offers pouring in after Crucell sold Italy-based Etna Biotech, the research arm for which he worked, to India's Zydus Cadila in 2008. Gluck, known for his ability in developing vaccines, preferred to stay on with his new employer, impressed by the opportunities that could emerge from the Indian connection. Excited by Cadila's commitment to the long haul, Gluck says it would not have been as good a call to work for any other established bigger multinational company. On the sidelines of the recent BioPharma Asia conference in Singapore, Gluck sat down with PharmAsia News' India bureau cheif to speak on issues ranging from funding of biotech initiatives to future vaccines and the research outlook in Asia.
You may also be interested in...
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015
Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015
Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.
Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015
AHMEDABAD, India - In a few months India's Zydus Cadila will join a handful of elite Indian companies like Dr. Reddy's and Cipla that managed to surpass the magic $1 billion mark in annual sales. Cadila says it has a comprehensive blueprint ready to cruise to $3 billion by 2015